-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Shenzhou Cell announced that its self-developed 14-valent HPV vaccine SCT1000 has entered clinical phase I/II studies and completed the enrollment of all 80 subjects
It is reported that Shenzhou Cell has been listed on the Science and Technology Innovation Board on June 23
Currently, HPV vaccines on the domestic market include: Merck’s quadrivalent vaccine and 9-valent vaccine, GSK and Wantai Biological’s bivalent vaccine